Facial features of lysosomal storage disorders

References

• Platt FM, d’Azzo A, Davidson BL, et al. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27.
   PubMed Web of Science ®Google Scholar
• Poswar FO, Vairo F, Burin M, et al. Lysosomal diseases: overview on current diagnosis and treatment. Genet Mol Biol. 2019;42(1 suppl 1):165–177.
   PubMed Web of Science ®Google Scholar
• Allanson JE, Cunniff C, Hoyme HE, et al. Elements of morphology: standard terminology for the head and face. Am J Med Genet A. 2009;149A(1):6–28.
   PubMed Web of Science ®Google Scholar
• Daykin E, Fleischer N, Abdelwahab M, et al. Investigation of a dysmorphic facial phenotype in patients with Gaucher disease types 2 and 3. Mol Genet Metab. 2021;134(3):274–280. ••Discusses the DeepGestalt technology and how it applies specifically to neuronopathic GD
   PubMed Web of Science ®Google Scholar
• Cox-Brinkman J, Vedder A, Hollak C, et al. Three-dimensional face shape in Fabry disease. Eur J Hum Genet. 2007;15(5):535–542.
   PubMed Web of Science ®Google Scholar
• Mishima H, Suzuki H, Doi M, et al. Evaluation of Face2Gene using facial images of patients with congenital dysmorphic syndromes recruited in Japan. J Hum Genet. 2019;64(8):789–794.
   PubMed Web of Science ®Google Scholar
• Hsieh TC, Bar-Haim A, Moosa S, et al. GestaltMatcher facilitates rare disease matching using facial phenotype descriptors. Nat Genet. 2022;54(3):349–357.
   PubMed Web of Science ®Google Scholar
• Sidransky E. Gaucher disease: insights from a rare Mendelian disorder. Discov Med. 2012;14(77):273–281.
   PubMed Web of Science ®Google Scholar
• Hong D, Zheng YY, Xin Y, et al. Genetic syndromes screening by facial recognition technology: VGG-16 screening model construction and evaluation. Orphanet J Rare Dis. 2021;16(1):344.
   PubMed Web of Science ®Google Scholar
• Weiss K, Gonzalez A, Lopez G, et al. The clinical management of Type 2 Gaucher disease. Mol Genet Metab. 2015;114(2):110–122.
   PubMedGoogle Scholar
• Schiffmann R, Sevigny J, Rolfs A, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020;43(5):1056–1059.
   PubMed Web of Science ®Google Scholar
• Jezela-Stanek A, Ciara E, Stepien KMN. Genetic profile, and clinical manifestation of mucolipidosis IV-A review and case series. Int J Mol Sci. 2020;21(12):4564.
   PubMed Web of Science ®Google Scholar
• Barth AL, de Magalhaes T, Reis ABR, et al. Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7 years follow-up. Mol Genet Metab Rep. 2017;12:62–68.
   PubMed Web of Science ®Google Scholar
• Pode-Shakked B, Finezilber Y, Levi Y, et al. Shared facial phenotype of patients with mucolipidosis type IV: a clinical observation reaffirmed by next generation phenotyping. Eur J Med Genet. 2020;63(7):103927.
   PubMed Web of Science ®Google Scholar
• Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, et al. Mucopolysaccharidosis Type I. Diagnostics (Basel). 2020;10(3):161.
   PubMedGoogle Scholar
• Clarke LA. Mucopolysaccharidosis Type I. [updated 2021 Feb 25]. . In: Adam MP, Everman DB, Mirzaa, GM, et al, editors. GeneReviews® [Internet].Seattle (WA): University of Washington; 2002. pp. 1993–2022.
   Google Scholar
• Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267–277.
   PubMed Web of Science ®Google Scholar
• Young ID, Harper PS. The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25(4):481–489.
   PubMed Web of Science ®Google Scholar
• Montano AM, Lock-Hock N, Steiner RD, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016;53(6):403–418.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Shediac R. Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment. Front Biosci (Landmark Ed). 2017;22(3):385–406.
   PubMedGoogle Scholar
• Lakhotia S, Sharma A, Shrivastava GP, et al. Maroteaux-Lamy syndrome. Indian J Pediatr. 2004;71(10):933–935.
   PubMedGoogle Scholar
• Marwaha A, Chitayat D, Meyn MS, et al. The point-of-care use of a facial phenotyping tool in the genetics clinic: enhancing diagnosis and education with machine learning. Am J Med Genet A. 2021;185(4):1151–1158.
   PubMed Web of Science ®Google Scholar
• Masson C, Cisse I, Simon V, et al. Fabry disease: a review. Joint Bone Spine. 2004;71(5):381–383.
   PubMed Web of Science ®Google Scholar
• Mehta A, Hughes DA.2002 Aug 5 [updated 2022 Jan 27]. In: Adam MP, Everman DB, Mirzaa GM,Pagon RA, Wallace, SE, Bean, LJH, Gripp KW, KW, Amemiya, A, editors. GeneReviews [Internet]. Seattle: University of Washington; 1993–2022.
   Google Scholar
• Ries M, Moore DF, Robinson CJ, et al. Quantitative dysmorphology assessment in Fabry disease. Genet Med. 2006;8(2):96–101.
   PubMed Web of Science ®Google Scholar
• Cospain A, Dubourg C, Gastineau S, et al. Incidental diagnosis of mucopolysaccharidosis type I in an infant with chronic intestinal pseudoobstruction by exome sequencing. Mol Genet Metab Rep. 2020;24:100621.
   PubMed Web of Science ®Google Scholar
• Ries M, Gal A. Genotype-phenotype correlation in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors Fabry Disease: perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis;2006.
   Google Scholar
• Arora V, Setia N, Dalal A, et al. Sialidosis type II: expansion of phenotypic spectrum and identification of a common mutation in seven patients. Mol Genet Metab Rep. 2020;22:100561.
   PubMed Web of Science ®Google Scholar
• Prada CE, Gonzaga-Jauregui C, Tannenbaum R, et al. Clinical utility of whole-exome sequencing in rare diseases: galactosialidosis. Eur J Med Genet. 2014;57(7):339–344.
   PubMed Web of Science ®Google Scholar
• Arvio MA, Peippo MM, Arvio PJ, et al. Dysmorphic facial features in aspartylglucosaminuria patients and carriers. Clin Dysmorphol. 2004;13(1):11–15.
   PubMed Web of Science ®Google Scholar
• Goodspeed K, Feng C, Laine M, et al. Aspartylglucosaminuria: clinical presentation and potential therapies. J Child Neurol. 2021;36(5):403–414.
   PubMed Web of Science ®Google Scholar
• Rosenberg RN. Circuits and circuit disorders: approaches to neuromodulation. JAMA Neurol. 2015;72(11):1232.
   PubMed Web of Science ®Google Scholar
• Arvio M, Mononen I. Aspartylglycosaminuria: a review. Orphanet J Rare Dis. 2016;11(1):162.
   PubMedGoogle Scholar
• Anikster Y, Shotelersuk V, Gahl WA. CTNS mutations in patients with cystinosis. Hum Mutat. 1999;14(6):454–458.
   PubMed Web of Science ®Google Scholar
• Baumner S, Weber LT. Nephropathic Cystinosis: symptoms, Treatment, and Perspectives of a Systemic Disease. Front Pediatr. 2018;6:58.
   PubMed Web of Science ®Google Scholar
• Bassim CW, Gautam P, Domingo DL, et al. Craniofacial and dental findings in cystinosis. Oral Dis. 2010;16(5):488–495.
   PubMed Web of Science ®Google Scholar
• Emma F, Hoff WV, Hohenfellner K, et al. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney Int. 2021;100(5):1112–1123.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos DS, Krasnewich D, Kaiser-Kupfer MI, et al. Classic nephropathic cystinosis as an adult disease. JAMA. 1993;270(18):2200–2204.
   PubMed Web of Science ®Google Scholar
• Servais A, Moriniere V, Grunfeld JP, et al. Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. Clin J Am Soc Nephrol. 2008;3(1):27–35.
   PubMed Web of Science ®Google Scholar
• Willems PJ, Gatti R, Darby JK, et al. Fucosidosis revisited: a review of 77 patients. Am J Med Genet. 1991;38(1):111–131.
   PubMed Web of Science ®Google Scholar
• Chkioua L, Amri Y, Chaima S, et al. Fucosidosis in Tunisian patients: mutational analysis and homology-based modeling of FUCA1 enzyme. BMC Med Genomics. 2021;14(1):208.
   PubMed Web of Science ®Google Scholar
• Zubarioglu T, Kiykim E, Zeybek CA, et al. Clinical and neuroradiological approach to fucosidosis in a child with atypical presentation. Ann Indian Acad Neurol. 2015;18(4):471–474.
   PubMed Web of Science ®Google Scholar
• Kaur A, Dhaliwal AS, Raynes H, et al. Diagnosis and supportive management of fucosidosis: a case report. Cureus. 2019;11(11):e6139.
   PubMed Web of Science ®Google Scholar
• Gray-Edwards HL, Regier DS, Shirley JL, et al. Novel biomarkers of human GM1 gangliosidosis reflect the clinical efficacy of gene therapy in a feline model. Mol Ther. 2017;25(4):892–903.
   PubMed Web of Science ®Google Scholar
• Feng Y, Huang Y, Zhao X, et al. Clinical and molecular characteristics of 11 Chinese probands with GM1 gangliosidosis. Metab Brain Dis. 2018;33(6):2051–2057.
   PubMed Web of Science ®Google Scholar
• Karimzadeh P, Jafari N, Nejad Biglari H, et al. GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): diagnosis and neuroimaging findings (An Iranian pediatric case series). Iran J Child Neurol. 2014;8(3):55–60.
   PubMedGoogle Scholar
• Yuskiv N, Higaki K, Stockler-Ipsiroglu S, et al. Disease. disease characteristics and treatment options of a distinct GLB1-related dysostosis multiplex. Int J Mol Sci. 2020;21(23):9121.
   PubMed Web of Science ®Google Scholar
• Anna Caciotti LC, Tonin R, Mei D, et al. Morquio B disease: from pathophysiology towards diagnosis. Mol Genet Metab. 2021;132(2):180–188.
   PubMedGoogle Scholar
• Cho SY, Jin D-K. GLB1-related disorders: GM1 gangliosidosis and Morquio B disease. J Gene Med. 2021;18(1):16–23.
   Google Scholar
• Annunziata I, d’Azzo A. Galactosialidosis: historic aspects and overview of investigated and emerging treatment options. Expert Opin Orphan Drugs. 2017;5(2):131–141.
   PubMed Web of Science ®Google Scholar
• Richard C, Tranchemontagne J, Elsliger MA, et al. Molecular pathology of galactosialidosis in a patient affected with two new frameshift mutations in the cathepsin A/protective protein gene. Hum Mutat. 1998;11(6):461–469.
   PubMed Web of Science ®Google Scholar
• Zammarchi E, Donati MA, Morrone A, et al. Early-infantile galactosialidosis: clinical, biochemical, and molecular observations in a new patient. Am J Med Genet. 1996;64(3):453–458.
   PubMed Web of Science ®Google Scholar
• Wreden CC, Wlizla M, Reimer RJ. Varied mechanisms underlie the free sialic acid storage disorders. J Biol Chem. 2005;280(2):1408–1416.
   PubMed Web of Science ®Google Scholar
• Aula N, Jalanko A, Aula P, et al. Unraveling the molecular pathogenesis of free sialic acid storage disorders: altered targeting of mutant sialin. Mol Genet Metab. 2002;77(1–2):99–107.
   PubMed Web of Science ®Google Scholar
• Kleta R, Aughton DJ, Rivkin MJ, et al. Biochemical and molecular analyses of infantile free sialic acid storage disease in North American children. Am J Med Genet A. 2003;120A(1):28–33.
   PubMed Web of Science ®Google Scholar
• Renlund M. Clinical and laboratory diagnosis of Salla disease in infancy and childhood. J Pediatr. 1984;104(2):232–236.
   PubMed Web of Science ®Google Scholar
• Aula P, Autio S, Raivio KO, et al. “Salla disease”: a new lysosomal storage disorder. Arch Neurol. 1979;36(2):88–94.
   PubMedGoogle Scholar
• Adams D, Wasserstein M. Free sialic acid storage disorders. In: Adam MP, Everman DB, Mirzaa GM, et al. editors. GeneReviews((R)). Seattle: University of Washington;1993–2022.
   Google Scholar
• Pantel JT, Hajjir N, Danyel M, et al. Efficiency of computer-aided facial phenotyping (deepgestalt) in individuals with and without a genetic syndrome: diagnostic accuracy study. J Med Internet Res. 2020;22(10):e19263. ••Investigates the accuracy of DeepGestalt analyses using images from17 differentic disorders
   PubMed Web of Science ®Google Scholar
• Lumaka A, Cosemans N, Lulebo Mampasi A, et al. Facial dysmorphism is influenced by ethnic background of the patient and of the evaluator. Clin Genet. 2017;92(2):166–171.
   PubMed Web of Science ®Google Scholar
• Liu H, Mo ZH, Yang H, et al. Automatic facial recognition of Williams-Beuren syndrome based on deep convolutional neural networks. Front Pediatr. 2021;9:648255.
   PubMed Web of Science ®Google Scholar
• Shaukat R, Raza SM, Yuns ZM, et al. Two brothers presenting with dysostosis multiplex. Egypt J Med Hum. 2016;17(3):243–246.
   Google Scholar